Study of TRM-1(TRAIL-R1 Monoclonal Antibody) in Subjects With Relapsed or Refractory Non-Small Cell Lung Cancer (NSCLC)

Completed · Phase 2

Conditions studied: Carcinoma, Non-Small-Cell Lung

In brief

The purpose of this study is to evaluate the efficacy and safety of TRM-1 in subjects with relapsed or refractory non-small cell lung cancer.

Key facts

Study ID

NCT00092924

Run by

Human Genome Sciences Inc.

Expected to finish

2005-03-01

Last updated by the study team

2013-08-02

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• University of Colorado Cancer Center — Denver, Colorado, United States
• Rush Medical College — Chicago, Illinois, United States
• Duke Comprehensive Cancer Center — Durham, North Carolina, United States
• Sarah Cannon Cancer Center — Nashville, Tennessee, United States
• MD Anderson — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.